



Breast Cancer in 2024 and Beyond

Friday, April 12, 2024, 2.00 PM – 6.00 PM CDT

Saturday, April 13, 2024, 8.00 AM – 12.00 PM CDT

Chair: Joyce O’Shaughnessy, MD

Faculty:

Peter Beitsch, MD

Adam Brufsky, MD, PhD

Monica Fornier, MD (Day 2 only)

Peter A. Kaufman, MD

Reshma Mahtani, DO

Kelly McCann, MD, PhD

Mark Pegram, MD

William Sikov, MD

AGENDA

Day 1

Time (CDT)	Topic	Presenter
2.00 PM – 2.10 PM (10 min)	Welcome and Introductions	Joyce O’Shaughnessy, MD
2.10 PM – 2.25 PM (15 min)	Current and Emerging Biomarkers and Testing Methodologies in Breast Cancer	Peter Beitsch, MD
2.25 PM – 2.50 PM (25 min)	Key Questions and Topics for Discussion	Joyce O’Shaughnessy, MD
2.50 PM – 2.55 PM (5 min)	Summary and 3 Key Takeaways	
2.55 PM – 3.10 PM (15 min)	Evolving Standards for Early-Stage HER2+ Breast Cancer	Mark Pegram, MD
3.10 PM – 3.35 PM (25 min)	Key Questions and Topics for Discussion	Joyce O’Shaughnessy, MD
3.35 PM – 3.40 PM (5 min)	Summary and 3 Key Takeaways	
3.40 PM – 3.55 PM (15 min)	Break	
3.55 PM – 4.10 PM (15 min)	Optimizing the Management of HER2+ mBC With Current and Emerging Agents	Adam Brufsky, MD, PhD

4.10 PM – 4.35 PM (25 min)	Key Questions and Topics for Discussion	Joyce O'Shaughnessy, MD
4.35 PM – 4.40 PM (5 min)	Summary and 3 Key Takeaways	
4.40 PM – 4.55 PM (15 min)	HER2-Low Breast Cancer – Expanding the Spectrum of Targetability	Reshma Mahtani, DO
4.55 PM – 5.15 PM (20 min)	Key Questions and Topics for Discussion	Joyce O'Shaughnessy, MD
5.15 PM – 5.20 PM (5 min)	Summary and 3 Key Takeaways	
5.20 PM – 5.35 PM (15 min)	Current and Future Prospects for High-Risk, Early-Stage, Triple-Negative Breast Cancer	William Sikov, MD
5.35 PM – 5.55 PM (20 min)	Key Questions and Topics for Discussion	Joyce O'Shaughnessy, MD
5.55 PM – 6.00 PM (5 min)	Summary and 3 Key Takeaways	
6.00 PM	Wrap-Up and Overview of Day 2 Activities	Joyce O'Shaughnessy, MD

Day 2

Time (CDT)	Topic	Presenter
8.00 AM – 8.05 AM (5 min)	Introduction and Review Agenda for Day 2	Joyce O'Shaughnessy, MD
8.05 AM – 8.20 AM (15 min)	Current and Investigational Approaches in Metastatic Triple-Negative Breast Cancer	Kelly McCann, MD, PhD
8.20 AM – 8.50 AM (30 min)	Key Questions and Topics for Discussion	Joyce O'Shaughnessy, MD
8.50 AM – 8.55 AM (5 min)	Summary and 3 Key Takeaways	
8.55 AM – 9.10 AM (15 min)	Expanding Options for High-Risk HR+, HER2- Early Breast Cancer	Joyce O'Shaughnessy, MD
9.10 AM – 9.35 AM (25 min)	Key Questions and Topics for Discussion	Joyce O'Shaughnessy, MD
9.35 AM – 9.40 AM (5 min)	Summary and 3 Key Takeaways	
9.40 AM – 9.55 AM (15 min)	Break	
9.55 AM – 10.10 AM (15 min)	Evolving Paradigms in HR+, HER2- Metastatic Breast Cancer	Peter A. Kaufman, MD
10.10 AM – 10.50 AM (40 min)	Key Questions and Topics for Discussion	Joyce O'Shaughnessy, MD
10.50 AM – 10.55 AM (5 min)	Summary and 3 Key Takeaways	
10.55 AM – 11.05 AM (10 min)	New Targets in Breast Cancer	Mark Pegram, MD
11.05 AM – 11.20 AM (15 min)	Key Questions and Topics for Discussion	Joyce O'Shaughnessy, MD
11.20 AM – 11.25 AM (5 min)	Summary and 3 Key Takeaways	
11.25 AM – 11.55 AM (30 min)	General Discussion: Future Directions in Breast Cancer Treatment	Joyce O'Shaughnessy, MD
11.55 AM – 12.00 PM (5 min)	Conclusions and Wrap-Up	Joyce O'Shaughnessy, MD